Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 1.15 (3.91%)
Data as of 09/22/17 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $28.25 with a 52 week high of $30.25 and a 52 week low of $13.61.
Recent NewsMore >>
09/20/17REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Six patients dosed at leading retinal surgery centers in the United States All participating study centers now active; next dose cohort is projected to start after review by the Data Safety Monitoring Board this month Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy; interim trial update expected by year-end 2017              ROCKVILLE, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology comp... 
Printer Friendly Version
08/31/17REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Aug. 31, 2017 (GLOBE NEWSWIRE) --  REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences: Citi 12th Annual Biotech Conference Dates: Wednesday, September 6 – Thursday, September 7 Location: Mandarin Oriental, Boston Panel: Gene Therapy Manufactu... 
Printer Friendly Version
08/25/17REGENXBIO to Acquire Dimension Therapeutics
Acquisition will add two lead product candidates to REGENXBIO’s metabolic disease franchise:     - DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial      - DTX401 for GSDIa, a late-stage preclinical candidate with an anticipated IND filing in early 2018 Acquisition will enhance REGENXBIO’s pipeline of gene therapy product candidates, with the potential to achieve multiple milestones through the end of 2018 REGENXBIO will host a conference call this morning... 
Printer Friendly Version
08/11/17REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists
RGX-314 trial design and subretinal delivery overview to be presented Enrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017 ROCKVILLE, Md., Aug. 11, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will present at the 35th Annual Scientific Meeting of the Am... 
Printer Friendly Version
Upcoming EventsMore >>
09/26/17 4:00 p.m. ET
REGENXBIO at Cantor Fitzgerald Global Healthcare Conference
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.